These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28638795)

  • 21. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
    Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
    Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma.
    Niedergethmann M; Wostbrock B; Sturm JW; Willeke F; Post S; Hildenbrand R
    Pancreas; 2004 Oct; 29(3):204-11. PubMed ID: 15367886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
    Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
    Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
    Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.
    Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V
    Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of gastric juice CA 19-9 and CEA levels in gastric carcinoma patients.
    Duraker N; Naci Celik A; Gençler N
    Eur J Surg Oncol; 2002 Dec; 28(8):844-9. PubMed ID: 12477476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative serum markers for individual patient prognosis in stage I-III colon cancer.
    Giessen-Jung C; Nagel D; Glas M; Spelsberg F; Lau-Werner U; Modest DP; Schulz C; Heinemann V; Di Gioia D; Stieber P
    Tumour Biol; 2015 Sep; 36(10):7897-906. PubMed ID: 25953265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy.
    Maire F; Voitot H; Aubert A; Palazzo L; O'Toole D; Couvelard A; Levy P; Vidaud M; Sauvanet A; Ruszniewski P; Hammel P
    Am J Gastroenterol; 2008 Nov; 103(11):2871-7. PubMed ID: 18775021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology.
    Rosty C; Christa L; Kuzdzal S; Baldwin WM; Zahurak ML; Carnot F; Chan DW; Canto M; Lillemoe KD; Cameron JL; Yeo CJ; Hruban RH; Goggins M
    Cancer Res; 2002 Mar; 62(6):1868-75. PubMed ID: 11912167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological diagnosis of pancreatic cancer by assaying carcinoembryonic antigen (CEA) in pure pancreatic juice.
    Nishida K; Yoshikawa T; Kondo M; Thiele HG
    Hepatogastroenterology; 1980 Dec; 27(6):488-94. PubMed ID: 7203382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein profiling in pancreatic juice for detection of intraductal papillary mucinous neoplasm of the pancreas.
    Shirai Y; Sogawa K; Yamaguchi T; Sudo K; Nakagawa A; Sakai Y; Ishihara T; Sunaga M; Nezu M; Tomonaga T; Miyazaki M; Saisho H; Nomura F
    Hepatogastroenterology; 2008; 55(86-87):1824-9. PubMed ID: 19102401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
    Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
    Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers.
    Kau SY; Shyr YM; Su CH; Wu CW; Lui WY
    J Am Coll Surg; 1999 Apr; 188(4):415-20. PubMed ID: 10195726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.
    Louhimo J; Alfthan H; Stenman UH; Haglund C
    Oncology; 2004; 66(2):126-31. PubMed ID: 15138364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer.
    Khomiak A; Brunner M; Kordes M; Lindblad S; Miksch RC; Öhlund D; Regel I
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33147766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas.
    Mehta S; Bhimani N; Gill AJ; Samra JS; Sahni S; Mittal A
    Front Oncol; 2021; 11():708963. PubMed ID: 34290990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma.
    Iuga C; Seicean A; Iancu C; Buiga R; Sappa PK; Völker U; Hammer E
    Proteomics; 2014 Apr; 14(7-8):945-55. PubMed ID: 24459066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic and prognostic biomarkers in pancreatic carcinoma.
    Liang JJ; Kimchi ET; Staveley-O'Carroll KF; Tan D
    Int J Clin Exp Pathol; 2009; 2(1):1-10. PubMed ID: 18830385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
    Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.